Dutasteride occupies an unusual position in the hair loss treatment landscape: it is arguably more potent than the FDA-approved standard (finasteride), supported by multiple controlled trials, and prescribed by dermatologists worldwide — yet it remains off-label for hair loss in most countries, including the United States.
Quick Answer
Dutasteride blocks both type I and type II 5-alpha reductase, reducing DHT by approximately 90-95% compared to finasteride's 60-70%. Studies show superior hair counts vs. finasteride, but it's not FDA-approved for hair loss and carries a similar side effect profile with potentially longer recovery times if side effects occur.
What Is Dutasteride?
Dutasteride (brand name Avodart) is a 5-alpha reductase inhibitor approved by the FDA in 2001 for the treatment of benign prostatic hyperplasia (enlarged prostate) at a dose of 0.5mg daily. It was developed by GlaxoSmithKline.
Unlike finasteride, which inhibits only the type II isoform of 5-alpha reductase, dutasteride inhibits both type I and type II isoforms. This dual inhibition is what makes it more potent as a DHT blocker.
Dutasteride is approved for hair loss in South Korea (since 2009, as Avodart) and Japan (since 2015, as Zagallo). In the US, EU, and UK, it remains off-label for this indication.
How Does Dutasteride Work?
The mechanism is the same as finasteride but broader in scope.
5-alpha reductase converts testosterone into dihydrotestosterone (DHT) — the androgen primarily responsible for follicle miniaturization in androgenetic alopecia. Two isoforms of this enzyme are present in scalp tissue:
- Type I: Found predominantly in sebaceous glands and the epidermis of the scalp
- Type II: Found in hair follicle dermal papilla cells — the primary target for hair loss treatment
Finasteride inhibits type II only, achieving approximately 60-70% reduction in serum DHT and roughly 60-65% reduction in scalp DHT.
Dutasteride inhibits both type I and type II, achieving approximately 90-95% reduction in serum DHT — roughly 30% greater suppression than finasteride.
The theory: more complete DHT suppression means less follicle miniaturization, means more preserved and potentially regrown hair. The clinical data largely supports this.
What Does the Evidence Say?
Head-to-Head vs. Finasteride
A pivotal 2006 phase II trial randomized 416 men with androgenetic alopecia to dutasteride (0.05, 0.1, 0.5, or 2.5mg), finasteride 5mg, or placebo for 24 weeks. Results at 24 weeks:
- Dutasteride 2.5mg produced significantly more hair growth than finasteride 5mg by target area hair count
- Only the 2.5mg dose was reported as superior to finasteride in this trial
- Dutasteride increased hair count versus placebo in a dose-dependent fashion
A 2014 randomized, placebo-controlled trial published in the Journal of the American Academy of Dermatology enrolled 917 men and compared dutasteride (0.02, 0.1, or 0.5mg) with finasteride 1mg and placebo over 24 weeks. Dutasteride 0.5mg showed significantly greater improvement than finasteride 1mg in hair count, hair width, and panel photographic assessment. A 2022 network meta-analysis estimated its hair count advantage over finasteride 1mg at about 7 hairs/cm² at 24 weeks.
Longer-Term Data
A 2016 open-label study of 120 Japanese men (with no finasteride comparison group) found dutasteride 0.5mg improved hair count, hair width, and global appearance from baseline over 52 weeks; drug-related adverse events were reported in 17% of patients, none leading to withdrawal.
Dutasteride has been approved for hair loss in South Korea since 2009 and in Japan since 2015, providing real-world long-term usage data. Prescribing rates in these markets are substantial.
Overall Efficacy
The evidence consistently shows dutasteride produces greater DHT suppression and somewhat superior hair counts compared to finasteride at standard doses. The clinical significance of this difference — how much more hair you'll see, and how much more noticeable it is — is moderate, not dramatic.
What Are the Side Effects?
The side effect profile of dutasteride is qualitatively similar to finasteride — the same mechanism, the same class of effects.
Reported Side Effects
In clinical trials for BPH (at the same 0.5mg dose), the most common sexual side effects in the first 6 months of treatment were:
- Decreased libido — 3.0% (vs. 1.4% on placebo)
- Erectile dysfunction — 4.7% (vs. 1.7% on placebo)
- Ejaculation disorders, including decreased ejaculate volume — 1.4% (vs. 0.5% on placebo)
- Breast disorders such as tenderness or enlargement (gynecomastia) — uncommon (0.5% in the first 6 months)
The Key Difference from Finasteride
Dutasteride's 5-week half-life has significant practical implications:
- If side effects occur, they may take longer to fully resolve after stopping
- DHT suppression persists for weeks to months after discontinuation
- Any semen parameter effects may also persist longer
Men considering dutasteride should weigh this against finasteride's 6-hour half-life, which means faster washout if problems arise.
Label Warnings: Blood Donation and Handling
Two warnings on the FDA label for dutasteride (Avodart) apply to anyone taking it, including off-label for hair loss:
- Don't donate blood while taking dutasteride or for at least 6 months after your last dose. The drug stays in the blood long enough that a pregnant transfusion recipient could be exposed.
- Women who are or may be pregnant should not handle the capsules. Dutasteride can be absorbed through the skin; if a capsule leaks onto skin, wash the area immediately with soap and water.
Post-Dutasteride Concerns
There is less literature on persistent adverse effects with dutasteride compared to the post-finasteride syndrome literature. This may reflect the drug's more limited use for hair loss, not necessarily a better safety profile.
Who Is Dutasteride For?
Good candidates
- Men with early to moderate androgenetic alopecia who tried finasteride and saw partial but insufficient response
- Men with more aggressive hair loss who want the most potent available DHT blocker
- Men in countries where dutasteride is approved for hair loss (South Korea, Japan) seeking a first-line option
- Men who understand the off-label nature and accept the regulatory status
Who should avoid it
- Men trying to conceive — dutasteride measurably affects semen parameters at 0.5mg
- Men with a low risk tolerance for side effects who prefer a drug with faster washout (finasteride may be more appropriate)
- Women who are pregnant or may become pregnant — absolutely contraindicated
- Men who haven't tried finasteride first — there's a strong argument to start with the FDA-approved option
How Does It Compare to Finasteride?
| Dutasteride | Finasteride | |
|---|---|---|
| FDA-approved for hair loss | No (off-label) | Yes (1mg) |
| DHT reduction | ~90-95% | ~60-70% |
| Isoforms blocked | Type I + II | Type II only |
| Half-life | ~5 weeks | ~6 hours |
| Hair count advantage | Modest-to-moderate advantage | Established standard |
| Evidence base | Strong but smaller | Extensive (25+ years) |
For most men starting treatment, finasteride is the appropriate first choice — FDA-approved, extensively studied, and the standard of care. Dutasteride is a reasonable step-up for finasteride partial responders or for men comfortable with the off-label status.
See our complete finasteride guide for a detailed comparison of the standard treatment.
Cost and Access
Dutasteride 0.5mg (generic) is available at retail pharmacies with a prescription. Generic pricing via GoodRx runs approximately $15-40/month — often cheaper than brand-name finasteride.
Several telehealth platforms prescribe dutasteride off-label for hair loss:
- RXSpan MD LegitScript Certified — prescribes dutasteride online after a licensed-physician review, and is one of the few services that offers it. It has no hair-specific landing page, so choose the hair-loss treatment once you're on their site.
- Happy Head — prescribes dutasteride in their custom compounded formulations
- Ro — prescribes dutasteride off-label with physician consultation
- Hims — offers dutasteride through their dermatology evaluation
See our Hims vs. Keeps vs. Ro comparison for platform details.
Our Verdict
Dutasteride is the more potent DHT blocker, and the clinical evidence supports modest superiority over finasteride for hair counts. For men who are finasteride partial responders, or who are comfortable with off-label prescribing and want the most aggressive DHT suppression available, dutasteride 0.5mg daily is a clinically reasonable choice.
The trade-offs are real: longer side effect persistence due to the long half-life, a smaller evidence base for hair loss specifically, and no FDA approval for this indication. These matter, but they don't make dutasteride inappropriate — just a treatment that warrants more careful consideration.
Start with finasteride if you're treatment-naive. Consider dutasteride as a step-up if finasteride's results are insufficient after 12-18 months, or work with a dermatologist who can evaluate your individual case.
Sources
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology. 2006;55(6):1014-1023. PMID: 17110217.
- Tsunemi Y, Irisawa R, Yoshiie H, et al. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. Journal of Dermatology. 2016;43(9):1051-1058. PMID: 26893187.
- Jung JY, Yeon JH, Choi JW, et al. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. International Journal of Dermatology. 2014;53(11):1351-1357. PMID: 24898559.
- U.S. Food and Drug Administration. Avodart (dutasteride) prescribing information. GlaxoSmithKline; 2001.
- Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2017;77(1):136-141. PMID: 28396101.
- Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology. 2014;70(3):489-498. PMID: 24411083.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatology. 2022;158(3):266-274. PMID: 35107565.
- Choi S, Kwon SH, Sim WY, Lew BL. Long-term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy. Journal of Dermatology. 2024;51(5):684-690. PMID: 38321615.
- Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1999;41(4):550-554. PMID: 10495374.